Object Pharma

Coming – May 19

A Transformative Approach To The Mental Health Crisis

Date and Time

May 19

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Object Pharma is creating a novel, non-systemic therapy to help solve today’s mental health crisis.

Depression affects more than 280 million people globally with an enormous personal and economic impact. In the U.S. alone costs exceed $327B each year, and according to the Depression and Bipolar Support Alliance, 60–70% of the 50,000 people who die by suicide suffer from depression. Current treatments like SSRis only work in 50% of patients.

Object’s lead candidate, OP01, is a neurotoxin-based therapy designed to deliver rapid, durable relief with a unique profile. It works by modulating neural signaling in emotional processing pathways. Unlike traditional antidepressants, OP01 is non-systemic, compatible with existing treatments, and dosed only a few times a year. In addition, this class of therapy is supported by a growing body of clinical evidence demonstrating meaningful improvements in patient outcomes.

Object Pharma owns one of the world’s few neurotoxin manufacturing platforms, is supported by a CDC-licensed facility, and generates approximately $3 million in annual revenue today. This provides both a strategic moat and a level of downside protection rarely seen at this stage.

Join our online event with Object Pharma board member, Dennis Fluet, to hear how their platform represents a “pipeline in a vial,” with applications across aesthetics, neurology, urology and additional psychiatric conditions.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.